Hematology & Immunohematology
Direct Coombs test - Direct antiglobulin test (DAT)
The direct Coombs test - officially known as the direct antiglobulin test (DAT) - is an immunohematological test that detects the presence of immunoglobulins (antibodies) and/or complement fractions attached directly to the surface of the patient's circulating erythrocytes. It is performed by removing the patient's red blood cells and bringing them into contact with an anti-human globulin reagent (Coombs serum) - antibodies of animal origin (rabbit or goat) directed against human IgG and/or the C3d fraction of complement. If IgG or C3d are present on the patient's red blood cells, the reagent will bridge them → agglutination visible macroscopically or in filtration gel → positive test. The direct Coombs test must be distinguished from the indirect Coombs test (indirect antiglobulin test - TAI), which detects free antibodies in the patient's serum capable of binding to test red blood cells - used primarily for extended blood grouping (phenotyping) and screening for irregular antibodies (RAI) prior to transfusion. The main indication for the direct Coombs test is the diagnostic work-up of any hemolytic anemia - including autoimmune hemolytic anemia (AHAI), hemolytic transfusion reactions, hemolytic disease of the fetus and newborn (HDNF), and drug-induced hemolytic anemias. The sensitivity of the standard direct Coombs test (in tube) for AHAI is 83-95 % - modern gel techniques (gel-centrifugation - DiaMed or Ortho technology) offer slightly higher sensitivity and better reproducibility. A positive direct Coombs test is not systematically associated with active hemolysis - an isolated positive DAT without anemia or biological signs of hemolysis is found in 1 to 15 % of hospitalized patients, and in 0.01 to 0.1 % of healthy blood donors - particularly those on medication.
Technical Principle and Specifics
- Anti-IgG reagent (monospecific): detects IgG bound to the surface of red blood cells; main characteristic of warm antibody AIHA (IgG — reactive at 37°C) and certain drug-induced anemias; IgG bound to erythrocytes activate complement and/or induce phagocytosis by splenic macrophages (hemolysis predominantly extravascular in the spleen).
- Anti-C3d reagent (monospecific): detects the C3d fraction of complement fixed on red blood cells; characteristic of cold antibody autoimmune hemolytic anemia (AIHA) (IgM - cryoagglutinins - which massively fix complement and then dissociate at 37°C, leaving C3d on erythrocytes); detection of C3d alone without IgG suggests cold antibody AIHA (cryoagglutinin) or paroxysmal cold hemoglobinuria (Donath-Landsteiner disease - biphasic IgG that fix complement in the cold and activate it upon warming)
- Polyspecific reagent (anti-IgG + anti-C3d): used as a first-line test in most laboratories - screening test; if positive, monospecific anti-IgG and anti-C3d tests to determine the type of immunoglobulin involved
- Modern techniques: gel centrifugation (DiaMed ID-Card, Ortho BioVue) - the most widely used in practice; confocal microscopy (detection of IgA - not detected by standard reagents - rare but real IgA AIHA); flow cytometry - ultra-sensitive detection of small quantities of IgG on red blood cells (standard technique direct Coombs negative but positive by cytometry → «Coombs-negative AIHA» - represents 5–10 % of AIHAs)
- SLIGHTLY POSITIVE DAT: Weakly positive result: 1+ or 2+ (on a scale of 0 to 4+) — requires clinical and biological correlation (complete hemolysis workup); isolated 1+ DAT without signs of hemolysis can be observed in diabetic patients, patients with chronic kidney disease, those who have received multiple transfusions, or those taking medications, without definite pathological significance.
Results and interpretation according to specifications
| TAD Result | Specific | Diagnostic orientation |
|---|---|---|
| Negative | — | Excludes (with high probability) a complement-fixing IgG or IgM AIHA; does not exclude an IgA AIHA (undetected) or a low-density IgG Coombs-negative AIHA (detectable only by flow cytometry or ultra-sensitive techniques); suggests other causes of hemolysis (corpuscular hemolysis—spherocytosis, G6PD, enzymopathy, hemoglobinopathy) |
| Positive anti-IgG only | IgG | Warm antibody autoimmune hemolytic anemia (most frequent—70–80% of WAIHA); drug-induced hemolytic anemia (hapten or immune complex mechanism); delayed post-transfusion hemolytic anemia (anti-IgG antibodies); hemolytic disease of the newborn from ABO or Rh incompatibility |
| Positive anti-C3d only | C3d | AIHA with cold agglutinins (IgM cold agglutinins - IgM dissociates at 37°C leaving only C3d); Donath-Landsteiner paroxysmal cold hemoglobinuria (biphasic IgG - rare, mostly in children after viral infection); certain drug-induced anemias (complex immune mechanism) |
| Positive anti-IgG + anti-C3d | IgG + C3d | Warm antibody autoimmune hemolytic anemia with complement activation - often a more severe form; drug-induced anemias (methyldopa, high-dose penicillin); certain systemic lupus erythematosus (SLE) with AIHA |
| Positive anti-IgG + anti-C3d (post-transfusion) | IgG + C3d | Acute or delayed hemolytic transfusion reaction — patient's anti-erythrocyte alloantibodies reacting with transfused red blood cells; emergency immunohematology workup (blood group, antibody screening, crossmatch) |
Causes of a positive direct Coombs test
| Cause | Biological mechanism and characteristics |
|---|---|
| Warm antibody (IgG) | The most frequent type of AIHA (–80%) involves IgG autoantibodies reactive at 37°C, most often directed against Rh system antigens (anti-e, anti-C, anti-D specificity, or panautoantibodies). Predominantly extravascular hemolysis occurs (spleen and liver). DAT: IgG ± C3d. Hemolysis workup: normocytic regenerative anemia, high reticulocyte count, elevated LDH, elevated indirect bilirubin, decreased haptoglobin. Idiopathic (50% %) or secondary: SLE (lupus — 25% %), B-cell lymphomas (CLL — 11% %), medications, infections (EBV, CMV, HIV). Treatment: Corticosteroids (prednisone 1 mg/kg/day) as first-line therapy — initial response 70–85% %; rituximab as second-line (anti-CD20); splenectomy if unresponsive; IVIG for severe cases. |
| AHAI with cold antibodies (IgM cold agglutinins) | 20–25 % des AHAI — auto-anticorps IgM monoclonaux ou polyclonaux réactifs à basse température (0–4°C optimale, 4–30°C cliniquement actifs) — fixent le complément jusqu'à la cascade C3d → hémolyse intravasculaire + agglutination des érythrocytes dans les extrémités froides (acrocyanose, phénomène de Raynaud) ; TAD : C3d seul (les IgM se sont dissociées à 37°C lors du prélèvement sanguin) ; LDH très élevée, bilirubinémie indirecte ; agglutination visible sur frottis (amas de globules rouges) ; indices érythrocytaires anormaux à la NFS (CGMH faussement élevée, VGM faussement élevé — les automates interprètent les agrégats comme de grands érythrocytes → réchauffer le tube à 37°C avant analyse) ; causes : idiopathique (personne âgée), infection à Mycoplasma pneumoniae (anti-I — polyclonal — temporary), EBV infection (anti-i — young adult), lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (monoclonal IgM — chronic); treatment: avoid cold, rituximab, bendamustine-rituximab (severe forms) |
| Paroxysmal cold hemoglobinuria (Donath-Landsteiner) | Très rare (< 5 % des AHAI) — auto-anticorps IgG biphasique anti-P (antigen P/Pk/P1 — globoside) — se fixent aux globules rouges au froid (0–15°C) puis activent le complément au réchauffement (37°C) → hémolyse intravasculaire brutale ; TAD : C3d (parfois IgG si prélèvement réalisé rapidement au froid) ; hémoglobinurie macroscopique (urines brun-rougeâtres) après exposition au froid ; test de Donath-Landsteiner (diagnostic de confirmation) ; chez l'enfant après virose (le plus souvent) — résolution spontanée ; chez l'adulte — syphilis tertiaire historiquement (rare de nos jours) |
| Medications (numerous mechanisms) | Hapten mechanism: penicillin and high-dose cephalosporins → covalently bind to erythrocyte membrane proteins → production of anti-drug IgG → IgG-positive TAD, extravascular hemolysis; ternary mechanism (immune complex): quinine, phenacetin, quinidine → formation of drug-antibody immune complexes → deposition on erythrocytes → complement activation → intravascular hemolysis ± simultaneous thrombocytopenia; true autoimmune mechanism: methyldopa (alpha-methyldopa - antihypertensive drug) → production of IgG directed against own erythrocyte antigens (Rh system anti-e) - IgG TAD positive in 10-15 % of methyldopa patients but clinical hemolysis in < 1 %; non-specific adsorption mechanism: 3rd generation cephalosporins → modification of erythrocyte membrane → non-specific adsorption of plasma proteins including IgG → positive TAD without hemolysis (functional false positive); other drugs: procainamide, isoniazid, diclofenac, fludarabine (severe AHAI), ibrutinib, levodopa |
| Hemolytic disease of the fetus and newborn (HDFN) | Maternal alloantibodies (IgG) crossing the placenta → binding to fetal erythrocytes carrying the target antigen → fetal hemolysis; main incompatibilities: anti-D (Rh) — the most severe, prevented by Rh prophylactic anti-D immunoglobulin in Rh− mothers); anti-c, anti-E, anti-Kell (Kell system — K — highly immunogenic), anti-Duffy, anti-Kidd; ABO incompatibility (mother O, infant A or B — anti-A or anti-B IgG) — frequent but usually moderate hemolysis; positive DAT on cord blood or newborn blood; treatment: phototherapy (bilirubin — neonatal jaundice), exchange transfusion if critical bilirubin, antenatal maternal IVIG if hydrops fetalis |
| Post-transfusion hemolysis | Acute hemolysis (within 24 hours): preformed alloantibodies in the recipient (ABO incompatibility - life-threatening emergency) or other systems; positive DAT on remaining transfused red blood cells; fever, chills, back pain, hemoglobinuria, shock - immediate discontinuation of transfusion and urgent immunohematological workup; delayed hemolysis (5-10 days post-transfusion): immune recall of low-titer alloantibodies not detected by pre-transfusion antibody screening → reactivation after contact with transfused red blood cells carrying the antigen; unexplained drop in hemoglobin + post-transfusion positive DAT -> document alloantibody and plan for compatible phenotyped units for future transfusions |
| Autoimmune diseases (SLE, Sharp syndrome, TTP) | SLE (systemic lupus erythematosus) — AIHA in 10–15 % of cases, often associated with autoimmune thrombocytopenia (Evans syndrome); Sharp syndrome (MCTD); thrombotic thrombocytopenic purpura (TTP) — thrombotic microangiopathy: DAT negative but microangiopathic hemolysis (schistocytes on blood smear) — mechanical, non-immune mechanism; hemolytic anemia of anemia of chronic diseases — DAT negative |
| Hematopoietic stem cell (HSC) transplant / solid organ | Minor ABO incompatibility (O donor, A or B recipient) → graft lymphocytes produce recipient's anti-A or anti-B alloantibodies (passenger lymphocyte syndrome) → hemolysis 5–15 days post-transplant; kidney transplant with major ABO incompatibility — risk of hemolysis of residual donor red blood cells by recipient's alloantibodies |
ℹ️
An isolated positive direct Coombs test without signs of hemolysis (normal LDH, normal haptoglobin, normal indirect bilirubin, unincreased reticulocytes) does not require treatment but should be monitored and investigated for its cause — notably, a complete inventory of medications (cephalosporins and penicillins are the most frequent causes of positive DAT without hemolysis in a hospital setting). The frequency of positive DAT without hemolysis increases with age, multiple transfusions, and certain chronic diseases (CLL, autoimmune diseases).
Additional assessment in the case of a positive direct Coombs test
- Hemolysis workup: hemoglobin (anemia), reticulocytes (bone marrow regeneration - elevated if active hemolysis), LDH (elevated in case of intra- or extravascular hemolysis - intracellular release), unconjugated indirect bilirubin (elevated during hemoglobin degradation into bilirubin), haptoglobin (collapsed < 0.1 g/L - most specific: haptoglobin is consumed when binding to free hemoglobin); hemoglobinuria and/or hemosiderinuria (severe intravascular hemolysis); blood smear (spherocytes in IgG AIHA, agglutinates/clumps in cold agglutinins, schistocytes in microangiopathy - TTP/HUS)
- Clarify the specificity of the direct Coombs test: monospecific anti-IgG and anti-C3d reagents (if polyspecific test is positive); antibody titration (+ or 1+ to 4+); elution of antibody fixed on red blood cells (acid or thermal technique) → identification of antigenic specificity (anti-e, anti-E, anti-D, panautoantibodies) — enables precise diagnosis of AIHA and guides the choice of compatible red blood cell concentrates for transfusions
- Etiological assessment: Complete blood count with smear (lymphocytosis in CLL), serum protein electrophoresis (monoclonal IgM peak in malignant cryoagglutinins), ANA/native anti-DNA (SLE), cryoagglutinin assay at 4°C (anti-I or anti-i specificity), infectious serologiesMycoplasma pneumoniae, EBV, CMV, HIV, hepatitis), a comprehensive list of current medications, lymphocyte count (immunophenotyping if CLL is suspected)
- In newborns: ABO and Rh blood typing on cord blood, DAT on cord blood, total and indirect bilirubin every 4–6 hours within the first 24–48 hours of life, daily measurement for 3–5 days if DAT positive, neurological monitoring (risk of kernicterus if bilirubin is critical)
Severe acute hemolysis — transfusion emergency
Dial 911 You should go to the emergency room immediately in case of acute severe hemolytic anemia: intense and sudden paleness, rapid jaundice, reddish-brown urine (hemoglobinuria), dyspnea at rest, back or flank pain (intravascular hemolysis), confusion, or altered consciousness. In case of acute hemolytic transfusion reaction during or after a transfusion — immediately stop the transfusion, keep the IV line open with 0.9% NaCl %, call a doctor urgently, and keep the blood bag and the collected tube for urgent transfusion workup (blood group, antibody screen, direct antiglobulin test, blood cultures). Incompatible ABO transfusion can be fatal within hours.
Consult at Clinique Omicron
Clinique Omicron physicians interpret a positive direct Coombs test in its clinical context (medications, transfusion history, autoimmune diseases), prescribe a hemolysis workup and a targeted etiological workup, and ensure referral to a hematologist for management of confirmed autoimmune hemolytic anemias. Consultations are available at our service points in Quebec and via telemedicine. To book an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not substitute for professional medical advice from a qualified healthcare provider. A positive direct Coombs test requires contextual medical interpretation—an isolated positive result does not necessarily indicate active hemolysis.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.